Last updated: September 2, 2026
Pegaptanib sodium, marketed as Macugen, was the first FDA-approved anti-VEGF therapy for neovascular age-related macular degeneration (AMD). Its commercial position deteriorated rapidly after the entry of ranibizumab and aflibercept, which offered broader VEGF inhibition and stronger visual-outcome profiles. Macugen remains an important case study in how a first-in-class ophthalmic biologic-like therapy can lose market share despite regulatory approval and patent protection.
What is pegaptanib sodium and how does it work?
Pegaptanib sodium is a pegylated RNA aptamer that selectively binds the VEGF165 isoform. It inhibits pathological retinal angiogenesis while leaving other VEGF isoforms less affected.
The product was developed by Eyetech Pharmaceuticals and commercialized in partnership with Pfizer. The FDA approved Macugen on December 17, 2004, for the treatment of neovascular AMD, also called wet AMD. The approved regimen was a 0.3 mg intravitreal injection every six weeks.[1]
Unlike ranibizumab and aflibercept, which inhibit multiple VEGF-A isoforms, pegaptanib was designed as an isoform-selective anti-VEGF treatment. That distinction became commercially disadvantageous as physicians increasingly favored broader VEGF inhibition and longer-duration dosing options.
What therapeutic category does Macugen occupy?
| Attribute |
Pegaptanib sodium |
| Brand |
Macugen |
| Active ingredient |
Pegaptanib sodium |
| Modality |
Pegylated RNA aptamer |
| Target |
VEGF165 |
| Initial FDA approval |
December 17, 2004 |
| Initial indication |
Neovascular AMD |
| Route |
Intravitreal injection |
| Original sponsor |
Eyetech Pharmaceuticals |
| Commercial partner |
Pfizer |
| FDA application |
NDA 021756 |
| Primary competitors |
Lucentis, Eylea, Avastin |
How did pegaptanib sodium perform commercially?
Macugen generated strong initial sales but experienced a steep decline after the arrival of Lucentis and off-label Avastin. Publicly reported sales reached approximately $266.8 million in 2006, according to industry reporting and company disclosures from the product’s early commercial period.[2]
The commercial trajectory was broadly as follows:
| Period |
Market position |
Financial direction |
| 2004-2005 |
First approved anti-VEGF drug for wet AMD |
Rapid launch adoption |
| 2006 |
Peak or near-peak commercial period |
Approximately $267 million in reported annual sales |
| 2007-2008 |
Market share erosion |
Declining revenue |
| 2009-2011 |
Secondary product in anti-VEGF therapy |
Sharp commercial contraction |
| After 2011 |
Limited commercial relevance |
Low or undisclosed sales |
The product’s launch benefited from a lack of approved anti-VEGF alternatives. That advantage ended when ranibizumab gained approval in 2006. Bevacizumab, although not FDA-approved for AMD, also became widely used off label because of its much lower cost.
Why did Macugen lose market share?
Pegaptanib faced four major commercial disadvantages.
First, it inhibited only VEGF165. Ranibizumab provided broader VEGF-A inhibition and demonstrated improved visual outcomes in pivotal AMD studies.
Second, the treatment required frequent intravitreal administration. Its six-week schedule was less attractive than competing products that could support longer treatment intervals in some patients.
Third, Macugen faced severe price competition from compounded bevacizumab. The Avastin-to-Lucentis pricing differential changed physician and payer behavior across ophthalmology.
Fourth, retinal specialists increasingly adopted products with stronger clinical evidence, including ranibizumab and later aflibercept. A first-to-market position did not translate into durable market leadership.
How does pegaptanib compare with Lucentis and Eylea?
| Product |
Active agent |
VEGF mechanism |
Initial wet AMD approval |
Commercial position |
| Macugen |
Pegaptanib sodium |
Selective VEGF165 inhibition |
2004 |
Largely displaced |
| Lucentis |
Ranibizumab |
Broad VEGF-A inhibition |
2006 |
Established anti-VEGF franchise |
| Eylea |
Aflibercept |
VEGF-A and placental growth factor trap |
2011 |
Major commercial leader |
| Avastin |
Bevacizumab |
Broad VEGF-A inhibition |
Not approved for AMD |
Widely used off label |
Lucentis established the clinical and commercial benchmark that Macugen could not match. Eylea later strengthened the competitive pressure through efficacy, dosing flexibility, and franchise expansion into other retinal diseases.
The market moved from an early single-product category to a competitive anti-VEGF market with differentiated dosing, broad labels, and major manufacturer support.
What patents protect pegaptanib sodium?
Pegaptanib protection was based primarily on aptamer composition, nucleic-acid ligand technology, pegylation, formulations, and therapeutic use. Core patent families associated with the technology included U.S. patents such as U.S. Patent No. 6,051,698 and related aptamer patents.[3]
The relevant patent categories were:
| Patent category |
Commercial relevance |
| Aptamer composition |
Covered nucleic-acid ligands binding target proteins |
| Pegylation chemistry |
Supported improved stability and pharmacokinetics |
| Therapeutic use |
Covered treatment of angiogenic eye disease |
| Ophthalmic formulation |
Addressed injectable product presentation and stability |
| Manufacturing process |
Potentially limited alternative production routes |
Patent protection was stronger during the launch period than at the end of the product’s commercial life. By the time meaningful generic or follow-on competition could have emerged, the product had already lost most of its clinical and economic value.
When did pegaptanib lose exclusivity?
The relevant U.S. patent terms were subject to filing dates, patent-term adjustment, patent-term extension, terminal disclaimers, and jurisdiction-specific prosecution history. The earliest core aptamer patents were filed in the 1990s and early 2000s, placing ordinary patent expiry principally in the late 2010s and early 2020s, depending on the specific patent and adjustment.
The FDA’s Orange Book should be used to determine the operative listed patent dates for NDA 021756. Patent expiry alone did not create a commercially attractive generic opportunity because Macugen demand had already contracted sharply.[4]
What was the FDA and Orange Book status of Macugen?
The FDA approved Macugen under NDA 021756 for neovascular AMD. The product was supplied as a sterile intravitreal injection and was administered by ophthalmologists.
Macugen was a conventional small-molecule NDA product for FDA approval purposes even though its active ingredient is an oligonucleotide aptamer rather than a traditional small molecule. It was not regulated through the biosimilar pathway used for therapeutic proteins such as ranibizumab or aflibercept.
The Orange Book historically listed patents associated with Macugen. Current listing status, expiration dates, and any changes to the active product record must be checked against the FDA’s current Orange Book data.[4]
Does pegaptanib have biosimilar risk?
Pegaptanib has limited conventional biosimilar risk because it is not a monoclonal antibody or recombinant protein. A follow-on developer would more likely face a complex generic or hybrid application strategy involving:
- analytical characterization of an oligonucleotide aptamer;
- demonstration of equivalent sequence and chemical modification;
- proof of comparable pegylation;
- sterile intravitreal manufacturing;
- device and container compatibility;
- clinical or pharmacodynamic requirements imposed by FDA review.
The main barrier would be commercial demand rather than only regulatory complexity. A technically approvable follow-on product would need to enter a market dominated by newer anti-VEGF agents.
Were there Paragraph IV challenges to Macugen?
No major, commercially consequential Paragraph IV challenge is widely associated with Macugen in the public record. The absence of a prominent challenge is consistent with the product’s declining revenue and weak return on investment for a generic entrant.
A Paragraph IV strategy would have faced several obstacles:
- Limited remaining branded sales.
- Complex active-ingredient characterization.
- Intravitreal sterile manufacturing requirements.
- Potential formulation and process patents.
- Physician preference for competing anti-VEGF therapies.
- Low likelihood of recovering litigation and development costs.
Macugen therefore illustrates a common pharmaceutical pattern: patent expiry risk can be legally real but economically immaterial when the product has already been displaced by superior alternatives.
What patent litigation and licensing agreements affected pegaptanib?
Eyetech and Pfizer entered a development and commercialization relationship for Macugen. Pfizer’s involvement provided global commercial scale during launch, while Eyetech contributed the product and underlying ophthalmology platform.
Eyetech was later acquired by OSI Pharmaceuticals. The transaction expanded OSI’s ophthalmology portfolio but occurred after Macugen had begun losing market share to Lucentis and Avastin.[5]
Publicly available records do not show a major late-stage patent litigation campaign comparable with the litigation surrounding Lucentis, Eylea, or other blockbuster biologics. Macugen’s key commercial disputes were more closely linked to product strategy, commercialization, and rights ownership than to prolonged generic patent litigation.
What caused the financial decline of pegaptanib sodium?
The revenue decline resulted from market substitution rather than a single patent event.
Clinical substitution
Clinical evidence favored broader VEGF blockade. The pivotal VISION trial supported pegaptanib’s approval, but later anti-VEGF therapies produced stronger visual-acuity outcomes in routine clinical practice.[6]
Pricing substitution
Compounded bevacizumab created a low-cost alternative. Although Avastin was not approved for AMD, its use became widespread after physicians and payers accepted off-label intravitreal administration.
Franchise substitution
Lucentis expanded the anti-VEGF category, while Eylea later captured substantial retina revenue. Both products benefited from additional indications and stronger manufacturer investment.
Administration burden
Macugen’s six-week injection interval did not provide a durable convenience advantage. Intravitreal therapy already imposes a high treatment burden, making dosing frequency commercially important.
Revenue exposure
At its peak, Macugen generated hundreds of millions of dollars annually. That level was material for its developers but modest compared with later anti-VEGF franchises. The more important financial consequence was the loss of future growth potential in retinal disease, not only the erosion of Macugen’s direct revenue.
What generic launch risks exist for pegaptanib sodium?
A potential generic or follow-on launch would face a mixed risk profile.
| Risk |
Assessment |
| Core composition patents |
Likely reduced after late-2010s expiry periods |
| Formulation patents |
Requires product-specific review |
| Manufacturing know-how |
Potentially meaningful for sterile aptamer production |
| FDA approval pathway |
More complex than a conventional oral generic |
| Market demand |
Weak |
| Pricing opportunity |
Limited by obsolete clinical positioning |
| Physician adoption |
Low without a major cost advantage |
| Litigation incentive |
Low because of limited branded revenue |
The primary risk is economic underperformance. Even if patent barriers were manageable, a developer would compete against established anti-VEGF drugs with stronger clinical demand and reimbursement infrastructure.
What is the geographic coverage and international status?
Macugen received approval in the United States and was authorized in other major markets, including the European Union. Its international commercial performance also declined as ranibizumab and aflibercept became standard treatments.
The European authorization was later withdrawn at the request of the marketing authorization holder for commercial reasons, according to European Medicines Agency records.[7] Withdrawal for commercial reasons does not necessarily indicate a safety or efficacy failure. It reflects the product’s limited commercial viability in that market.
Geographic patent coverage depended on national filings and validation of the underlying aptamer and formulation families. U.S. expiry did not automatically terminate rights in Europe, Japan, or other jurisdictions.
How strong is the pegaptanib patent estate?
The patent estate was strategically strong during the product’s launch window because it protected a novel aptamer platform and a clinically validated ophthalmic use. Its practical strength declined for three reasons:
- core patent terms moved toward expiry;
- competing products reduced the value of exclusivity;
- the product’s narrow VEGF165 mechanism limited lifecycle opportunities.
The estate was strongest as a first-mover barrier and weakest as a late-life commercial defense. Manufacturing and formulation claims may have provided residual protection, but they were unlikely to restore market leadership.
What is the outlook for pegaptanib sodium?
Pegaptanib is unlikely to regain material market share in wet AMD. Its residual commercial value is limited by the dominance of aflibercept, ranibizumab, bevacizumab, and newer long-acting retinal therapies.
Potential residual value could exist in:
- legacy patient populations;
- selected patients requiring VEGF165-selective inhibition;
- regional markets with limited access to newer agents;
- licensing of aptamer technology rather than continued Macugen commercialization.
The broader strategic value of pegaptanib lies in its validation of aptamers as therapeutic agents and its role in establishing VEGF inhibition as the core treatment paradigm for neovascular AMD.
Key Takeaways
- Pegaptanib sodium was the first FDA-approved anti-VEGF therapy for wet AMD.
- Macugen sales reached approximately $267 million around 2006 before declining sharply.
- Ranibizumab, bevacizumab, and aflibercept displaced pegaptanib through broader VEGF inhibition, stronger clinical adoption, lower cost, or better commercial positioning.
- Core patent protection was based on aptamer, pegylation, formulation, use, and manufacturing claims.
- No major commercially consequential Paragraph IV challenge is widely associated with Macugen.
- Pegaptanib is not a conventional biosimilar product; a follow-on applicant would face a complex oligonucleotide and sterile-injection development pathway.
- Patent expiry became less important than clinical obsolescence and low remaining demand.
- The European authorization was withdrawn for commercial reasons.
- Macugen’s current value is primarily historical and technological, not as a growth pharmaceutical asset.
FAQs
Is pegaptanib sodium still FDA approved?
Macugen received FDA approval under NDA 021756. Its commercial availability and current marketing status should be distinguished from the continued existence of the original approval record.
Was Macugen more effective than Lucentis?
Macugen was effective relative to placebo in its pivotal development program, but Lucentis established stronger visual-outcome performance and became the preferred broad VEGF-A inhibitor for wet AMD.
Can pegaptanib sodium be substituted with bevacizumab?
Bevacizumab has been used off label by intravitreal injection, but substitution is a clinical decision involving formulation, compounding, dosing, safety, and physician judgment.
Is pegaptanib sodium a biologic drug?
Pegaptanib is a synthetic, pegylated RNA aptamer. It is biologically active but does not fit the conventional monoclonal-antibody or recombinant-protein category associated with biosimilar competition.
What was the main commercial failure of Macugen?
The central failure was mechanism and market positioning. Selective VEGF165 inhibition became less attractive after broader anti-VEGF agents demonstrated stronger clinical utility and captured physician adoption.
References
- U.S. Food and Drug Administration. (2004). FDA approves Macugen for wet age-related macular degeneration. https://www.fda.gov
- Pfizer Inc. (2007). Annual report 2006. https://www.pfizer.com
- U.S. Patent and Trademark Office. (1999). U.S. Patent No. 6,051,698, Nucleic acid ligands. https://patents.google.com/patent/US6051698
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
- OSI Pharmaceuticals, Inc. (2005). OSI Pharmaceuticals completes acquisition of Eyetech Pharmaceuticals. https://www.sec.gov
- Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Jr., Feinsod, M., & Guyer, D. R. (2004). Pegaptanib for neovascular age-related macular degeneration. New England Journal of Medicine, 351(27), 2805-2816.
- European Medicines Agency. (2011). Macugen: Withdrawal of marketing authorisation. https://www.ema.europa.eu
